World's First CAR-T Therapy for Solid Tumors Available in China Soon

World's First CAR-T Therapy for Solid Tumors Available in China Soon

A New Hope for Patients with Advanced Gastric and Pancreatic Cancers SHANGHAI, April 9, 2026 /PRNewswire/ -- A groundbreaking new CAR-T cell therapy for advanced gastrointestinal cancers is expected to become available in China in the first half of...

CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025

CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025

SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the research results of the Phase Ib registrational clinical trial...

CARsgen's Satri-cel Granted Priority Review by the NMPA

CARsgen's Satri-cel Granted Priority Review by the NMPA

SHANGHAI, May 28, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the Center for Drug Evaluation (CDE) of China's National Medical...

CARsgen's Satri-cel Abstract Available on ASCO Website

CARsgen's Satri-cel Abstract Available on ASCO Website

SHANGHAI, May 23, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that an abstract of the research results of the confirmatory Phase II...

menu
menu